Today's DCA partnership announcement completes a strategic picture that has been forming for months. Tandem Health is now embedded in both UK healthcare markets simultaneously — and the dual positioning is not accidental.
The NHS Strategy
Tandem's Accurx partnership, launched in April 2025, embedded Accurx Scribe (powered by Tandem) across 98% of GP practices — reaching 200,000+ NHS clinicians in primary and secondary care. The integration writes back directly to EMIS and SystmOne, the two dominant NHS clinical systems. This is one of the largest healthcare AI rollouts globally.
The NHS value proposition: admin reduction and system efficiency. NHS clinicians spend approximately one-third of their time on administrative documentation. Tandem reduces documentation time by 29% (based on the 375,000-note Capio evaluation), with a median editing time of 93 seconds per note. At NHS scale, this translates into hundreds of thousands of recovered clinical hours annually.
The Private Sector Strategy
The DCA partnership, announced today, embeds Tandem into one of the UK's largest private telehealth platforms — 60,000+ consultations per month, 1,500+ insurer and corporate clients, 24/7 GP and ACP access. Tandem has integrated with DCA's Microsoft Dynamics-based EHR.
The private sector value proposition is different: speed, patient experience, and operational scalability. DCA needs to deliver high-quality consultations at volume while keeping operational costs sustainable. AI documentation embedded in the workflow — not as an optional clinician tool but as platform infrastructure — achieves this.
Why Both Markets Matter
NHS provides scale and credibility. 200,000+ clinicians is an adoption number that no competitor can match in the UK. NHS deployment validates clinical safety, governance compliance, and real-world effectiveness. When Tandem approaches any healthcare organisation globally, the NHS deployment is proof of performance at scale.
Private provides monetisation and faster iteration. NHS procurement is slow. Private healthcare moves faster — DCA can adopt, iterate, and expand AI features without the multi-year procurement cycles that constrain NHS innovation. Private partnerships also provide revenue at commercial pricing, funding the R&D that benefits both markets.
The Broader Pattern
Tandem is not the only vendor pursuing dual-market coverage, but it is the furthest along. Tortus AI has 3,500+ practices and NHS trust deployments. Heidi Health has strong individual clinician adoption across both sectors. But Tandem's combination of Accurx (NHS infrastructure) and DCA (private infrastructure) gives it embedded presence in both markets' dominant platforms — not just individual clinician usage.
The Italy expansion through Humanitas (announced last week) adds a third dimension: European hospital-system-level deployment. Tandem is building coverage across NHS primary care, UK private telehealth, and European hospital systems simultaneously.
What This Means for Clinicians
Expect to encounter the same AI tools in both your NHS clinic and private digital platform work. The AI scribe you use via Accurx in your NHS GP surgery uses the same Tandem technology that DCA's virtual care clinicians will use in private consultations. The tool is becoming invisible — embedded in the clinical environment rather than chosen by the individual clinician.
This has implications for training, governance, and clinical autonomy. When AI documentation is platform infrastructure rather than a personal tool, the clinician's relationship with it changes. The admin burden decreases — but so does the choice about whether and how AI participates in your clinical workflow.
The strategic signal is clear: clinical AI in the UK is moving from optional tool to default infrastructure. Tandem's dual-market positioning ensures it is present wherever that infrastructure is being built.